Novozymes A/S (OTCMKTS:NVZMY) Short Interest Up 87.2% in July

Novozymes A/S (OTCMKTS:NVZMYGet Free Report) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 26,584 shares, a growth of 87.2% from the June 30th total of 14,203 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 76,138 shares, the short-interest ratio is currently 0.3 days.

Analysts Set New Price Targets

Several brokerages recently issued reports on NVZMY. Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Kepler Capital Markets upgraded Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy”.

Check Out Our Latest Report on Novozymes A/S

Novozymes A/S Price Performance

OTCMKTS NVZMY opened at $63.95 on Thursday. The firm’s fifty day simple moving average is $61.45 and its two-hundred day simple moving average is $60.45. The company has a current ratio of 1.67, a quick ratio of 1.03 and a debt-to-equity ratio of 0.27. Novozymes A/S has a 12-month low of $49.90 and a 12-month high of $66.82. The firm has a market capitalization of $26.51 billion, a P/E ratio of 43.21, a P/E/G ratio of 3.01 and a beta of 0.92.

Novozymes A/S (OTCMKTS:NVZMYGet Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.51 EPS for the quarter, missing the consensus estimate of $0.82 by ($0.31). Novozymes A/S had a net margin of 14.22% and a return on equity of 6.52%. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Analysts forecast that Novozymes A/S will post 2.43 EPS for the current fiscal year.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

See Also

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.